UBS Group’s ACELYRIN SLRN Stock Holding History

UBS Group’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-103,525	Closed	-$256K	–	10787
2025 Q1	$256K	Sell	103,525 -83,480	-45%	-$198K	﹤0.01%	6365
2024 Q4	$587K	Buy	187,005 +148,199	+382%	+$718K	﹤0.01%	5725
2024 Q3	$191K	Buy	38,806 +8,821	+29%	+$45.5K	﹤0.01%	5908
2024 Q2	$132K	Sell	29,985 -221,058	-88%	-$1.04M	﹤0.01%	5965
2024 Q1	$1.69M	Buy	251,043 +249,208	+13,581%	+$1.89M	﹤0.01%	4101
2023 Q4	$13.7K	Buy	1,835 +1,317	+254%	+$11.2K	﹤0.01%	7303
2023 Q3	$5.27K	Sell	518 -1,563	-75%	-$33.2K	﹤0.01%	7383
2023 Q2	$43.5K	Buy	+2,081	New	+$42.6K	﹤0.01%	6550

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's SLRN Position: Q2 2025 in Review

UBS Group sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 103,525 shares — an estimated $256K sold.

UBS Group first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $1.69M in Q1 2024. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

UBS Group reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
UBS Group sold 103,525 ACELYRIN shares in Q2 2025, an estimated $256K.
UBS Group first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
UBS Group's ACELYRIN position peaked at $1.69M in Q1 2024.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.